Byterna Therapeutics
Contact Us
← All news & publications

23 OCT 2025 · FINANCING

Angel and Angel+ financing supports the in vivo CAR-T pipeline

Byterna announced Angel and Angel+ financing with investment from SunNovo Pharma and Efung Capital, supporting its circular mRNA and in vivo CAR-T pipeline.

BYTERNA / FINANCING MILESTONE

STRATEGIC MOMENTUM FOR RNA MEDICINES

Angel & Angel+financing completed.

OUR INVESTORS

SunNovo Pharma logoSunNovo PharmaInvestor
Efung Capital logoEfung CapitalInvestor

The financing announcements described support for the company’s circular mRNA and in vivo CAR-T development work.